Ipilimumab for patients with advanced mucosal melanoma (Q33777469)

29 July 2017

Ipilimumab for patients with advanced mucosal melanoma (English)

1 reference

29 July 2017

0 references

8

Keith T Flaherty

1 reference

29 July 2017

18

Jedd D Wolchok

1 reference

29 July 2017

19

F Stephen Hodi

1 reference

29 July 2017

17

Sacha Gnjatic

1 reference

29 July 2017

5

Katherine S Panageas

1 reference

29 July 2017

13

Sandra P D'Angelo

1 reference

29 July 2017

7

Nageatte Ibrahim

1 reference

29 July 2017

1

Michael A Postow

1 reference

29 July 2017

4

Nikhil Ramaiya

1 reference

29 July 2017

Jason J Luke

2

1 reference

29 July 2017

Mark J Bluth

3

1 reference

29 July 2017

Donald P Lawrence

6

1 reference

29 July 2017

Ryan J Sullivan

9

1 reference

29 July 2017

Patrick A Ott

10

1 reference

29 July 2017

Margaret K Callahan

11

1 reference

29 July 2017

James J Harding

12

1 reference

29 July 2017

Mark A Dickson

14

1 reference

29 July 2017

Gary K Schwartz

15

1 reference

29 July 2017

Paul B Chapman

16

1 reference

29 July 2017

Richard D Carvajal

20

1 reference

29 July 2017

28 May 2013

1 reference

29 July 2017

1 reference

29 July 2017

18

1 reference

29 July 2017

6

1 reference

29 July 2017

726-732

1 reference

NRAS mutation status is an independent prognostic factor in metastatic melanoma

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

The role of abdominoperineal resection as surgical therapy for anorectal melanoma.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Somatic activation of KIT in distinct subtypes of melanoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Distinct sets of genetic alterations in melanoma

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Determinants of BRAF mutations in primary melanomas

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Mutations of the BRAF gene in human cancer

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Autoantibodies against cancer antigens.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Biochemotherapy in patients with advanced head and neck mucosal melanoma

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Biochemotherapy in patients with metastatic anorectal mucosal melanoma.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4063400

Primary mucosal malignant melanoma of the head and neck

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23716015

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1634/THEONCOLOGIST.2012-0464

1 reference

29 July 2017

1 reference

29 July 2017

1 reference